Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (GRCE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
grce · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Grace Therapeutics, Inc.You GRCE | $37M | N/A | — | -$0.48 |
 Actinium Pharmaceuticals, Inc. ATNM | $33M | N/A | — | -$1.09 |
 CalciMedica, Inc. CALC | $15M | N/A | — | -$0.00 |
 Lantern Pharma Inc. LTRN | $53M | N/A | — | -$1.57 |
 LAVA Therapeutics N.V. LVTX | $46M | N/A | — | -$0.94 |
 OnKure Therapeutics, Inc. OKUR | $63M | N/A | — | -$4.40 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Grace Therapeutics, Inc. (GRCE) measures how much investors pay for each dollar of the company's trailing earnings. GRCE's current PE ratio of N/A is calculated by dividing its stock price of $2.37 by its TTM earnings per share of -$0.48.
Frequently asked questions
GRCE pe ratio · 6 questionsGRCE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.37 and TTM EPS of -$0.48. Data sourced from Financial Modeling Prep via GRCE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Grace Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09